{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":31,"n_cols":5,"rows_kept":31,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[11,4,11,5],[12,2,12,3],[12,4,12,5],[13,2,13,3],[15,2,15,3],[16,2,16,3],[17,2,17,3],[18,2,18,3],[19,2,19,3],[21,2,21,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA990004476160403321"]
[null,null,"Autore",null,"Przyluski, Jean"]
[null,null,"Titolo",null,"La participation / Jean Przyluski"]
[null,null,"Pubbl/distr/stampa",null,"Paris : Alcan Presses Universitaires de France, 1940"]
[null,null,"Descrizione fisica",null,"XII, 169 p. ; 18 cm"]
[null,null,"Collana",null,"Nouvelle encyclopédie philosophique ; 23"]
[null,null,"Locazione",null,"FLFBC"]
[null,null,"Collocazione",null,"5/ IV E 60"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,"2.","Record Nr.",null,"UNINA9910861028703321"]
[null,null,"Titolo",null,"Best Practices : Position and Guidance Documents of ASHP"]
[null,null,"Pubbl/distr/stampa",null,"Bethesda : , : American Society of Health-System Pharmacists, , 2022"]
[{"$nulls":4},"©2024"]
[null,null,"ISBN",null,"1-58528-704-0"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (2030 pages)"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Best Practices: Position &amp -- Guidance Documents of ASHP -- Title page -- Copyright -- Contents -- Page Locator for Guidance Documents by Type and Title -- Introduction -- Mission Statement -- Vision Statement -- Automation and Information Technology -- Positions: -- *2303 - Interoperability of Patient-Care Technologies -- *2304 - Patient Medication Delivery Systems -- *2332 - Barcoding of Lot Number and Expiration Date -- *2204 - Mobile Health Tools, Clinical Apps, and Associated Devices -- *2246 - Autoverification of Medication Orders -- *2255 - Therapeutic Indication for Prescribed Medications -- *2147 - Pharmacist's Role in Healthcare Information Systems -- *2015 - Network Connectivity and Interoperability for Continuity of Care -- 1529 - Online Pharmacy and Internet Prescribing -- 1418 - Risk Assessment of Health Information Technology -- *1212 - Clinical Decision Support Systems -- 1020 - Role of Pharmacists in Safe Technology Implementation -- 0712 - Electronic Health and Business Technology and Services -- 0105 - Computerized Prescriber Order Entry -- 9813 - Regulation of Automated Drug Distribution Systems -- Statements: -- Bar-Code-Enabled Medication Administration Technology -- Bar-Code Verification During Inventory, Preparation, and Dispensing of Medications -- Pharmacist's Role in Clinical Informatics -- Pharmacist's Role with Respect to Drug Delivery Systems and Administration Devices -- *Pharmacy Technician's Role in Pharmacy Informatics -- *Telehealth Pharmacy Practice -- *Use of Artificial Intelligence in Pharmacy -- Use of Social Media by Pharmacy Professionals -- Guidelines: -- Design of Database-Driven Clinical Decision Support: Strategic Directions for Drug Database and Electronic "]
[{"$nulls":4},"Health Records Vendors -- Pharmacy Planning for Implementation of CPOE Systems in Hospitals and Health Systems."]
[{"$nulls":4},"Remote Medication Order Processing -- *Safe Use of Automated Compounding Devices for the Preparation of Parenteral Nutrition Admixtures -- *Safe Use of Automated Dispensing Cabinets -- Drug Distribution and Control Positions: -- Positions: -- *2222 - Pharmacist's Role in Medication Procurement, Distribution, Surveillance, and Control -- *2145 - Reduction of Unused Prescription Drug Products -- 2042 - Controlled Substances Diversion Prevention -- 0303 - Pharmacy Drug Theft -- 9903 - Optimizing the Medication-Use Process -- Guideline: -- *Preventing Diversion of Controlled Substances -- PROCUREMENT -- Guidelines: -- Managing Drug Product Shortages -- Selecting Pharmaceutical Manufacturers and Suppliers -- PREPARATION AND HANDLING -- Positions: -- *2139 - Safe and Effective Extemporaneous Compounding -- *2024 - Safety and Efficacy of Compounded Topical Formulations -- 1903 - Compounded Sterile Preparation Verification -- 1813 - Use of Closed-System Transfer Devices to Reduce Drug Waste -- 0903 - Pharmaceutical Waste -- 0614 - Safe Disposal of Patients' Home Medications -- Guidelines: -- Compounding Sterile Preparations -- Handling Hazardous Drugs -- TAB: -- Compounding Nonsterile Products in Pharmacies -- DISTRIBUTION -- Positions: -- *2022 - Dispensing by Nonpharmacists and Nonprescribers -- 1913 - Pharmaceutical Distribution Systems -- *0310 - Technician-Checking-Technician Programs -- Statements: -- Pharmacist's Responsibility for Distribution and Control of Drug Products -- Unit Dose Drug Distribution -- TABs: -- Hospital Drug Distribution and Control -- Repackaging Oral Solids and Liquids in Single Unit and Unit Dose Packages -- Single Unit and Unit Dose Packages of Drugs -- Education and Training -- Positions: -- 2301 - Education and Training in Digital Health -- 2329 - Well-Being and Resilience of the Pharmacy Workforce."]
[{"$nulls":4},"*2201 - State-Specific Requirements for Pharmacist and Pharmacy Technician Continuing Education -- *2203 - Preceptor Skills and Abilities -- *2216 - Career Counseling -- *2230 - Advancing Diversity, Equity, and Inclusion in Education and Training -- *2231 - Cultural Competency -- *2104 - Fostering Leadership Development -- *2105 - Interprofessional Education and Training -- *2106 - Pharmacy Education and Training Models -- *2107 - Pharmacy Internships -- *2027 - Residency Training for Pharmacists Who Provide Direct Patient Care -- 1911 - Pharmacy Expertise in Sterile Compounding -- 1912 - Pharmacy Technician Training and Certification -- 1917 - Pharmacy Technician Student Drug Testing -- 1918 - Minimum Educational Qualification Standards for Pharmacists -- *1826 - Student Pharmacist Drug Testing -- 1827 - Collaboration on Experiential Education -- 1706 - ASHP Guidelines, Statements, and Professional Policies as an Integral Part of the Educational Process -- 1317 - Education and Training in Health Care Informatics -- 1203 - Qualifications of Pharmacy Technicians in Advanced Roles -- 1108 - Quality of Pharmacy Education and Expansion of Colleges of Pharmacy -- 1109 - Residency Equivalency -- 1112 - Innovative Residency Models -- 1008 - Employment Classification and Duty Hours of Pharmacy Residents -- 0913 - Pharmacy Student Experiences in Medically Underserved Areas -- 0916 - Continuing Professional Development -- 0917 - Pharmacy Residency Training -- 0704 - Residency Programs -- 0510 - Communication Among Health-System Pharmacy Practitioners, Patients, and Other Health Care Providers -- 0325 - Public Funding for Pharmacy Residency Training -- Statement: -- *Precepting as a Professional Obligation -- Endorsed: -- Definitions of Pharmacy "]
[{"$nulls":4},"Residencies and Fellowships -- Ethics -- Positions: -- *2320 - Pharmacoequity."]
[{"$nulls":4},"*2036 - Racial and Discriminatory Inequities -- 1704 - Medical Aid in Dying -- 1531 - Pharmacist Role in Capital Punishment -- 1403 - Pharmacist's Role on Ethics Committees -- 1116 - Ethical Use of Placebos in Clinical Practice -- 0610 - Pharmacist's Right of Conscience and Patient's Right of Access to Therapy -- 0013 - Patient's Right to Choose -- Statements: -- *Leadership as a Professional Obligation -- Pharmacist's Decision-making on Assisted Suicide -- *Professionalism -- Guideline: -- Pharmacists' Relationships with Industry -- Endorsed: -- Code of Ethics for Pharmacists -- Formulary Management (Medication-Use Policy Development) -- Positions: -- *2308 - Pharmacogenomics -- *2016 - Medication Formulary System Management -- *1802 - Gene Therapy -- 1820 - Medical Devices -- 0817 - Generic Substitution of Narrow Therapeutic Index Drugs -- 8708 - Therapeutic Interchange -- Statement: -- Use of Medications for Unlabeled Uses -- Guidelines: -- *Medication-Use Evaluation -- *Pharmacy and Therapeutics Committee and the Formulary System -- Endorsed: -- Principles of a Sound Drug Formulary System -- Government, Law, and Regulation -- Positions: -- *2306 - Support for FDA Expanded Access (Compassionate Use) Program -- *2307 - Biosimilar Medications -- *2317 - Emergency Medical Kits -- *2322 - Availability and Use of Fentanyl Test Strips -- *2323 - DEA Scheduling of Controlled Substances -- *2325 - Nonprescription Availability of Self-Administered Influenza Antivirals -- *2326 - Over-the-Counter Availability of Hormonal Contraceptives -- *2330 - Pharmacist Prescribing Authority for Antiretroviral Therapy for the Prevention of HIV/AIDS -- *2239 - Drug Pricing Proposals -- *2101 - Direct-to-Consumer Clinical Genetic Tests -- *2111 - Pharmacist Involvement in the Strategic National Stockpile -- *2112 - Medication Price-Gouging Laws."]
[{"$nulls":4},"*2114 - FDA Requirement for Dose-Response Information -- *2115 - Medical Cannabis -- *2118 - Supply Chain Resilience During Disasters and Public Health Emergencies -- *2141 - Pharmacist Engagement in and Payment for Telehealth -- *2142 - Pharmacy Services in a State of Emergency -- *2144 - Agricultural Use of Hormone and Prohormone Therapy -- *2004 - Evaluation of Abuse-Deterrent Drug Mechanisms -- *2005 - Quality Consumer Medication Information -- *2007 - Use of Surrogate Endpoints for FDA Approval of Drug Uses -- *2012 - Importation of Drug Products -- *2013 - Public Quality Standards for Biologic Products -- *2019 - Access to Affordable Healthcare -- *2021 - Funding, Expertise, and Oversight of State Boards of Pharmacy -- *2023 - New Categories of Licensed Pharmacy Personnel -- *2025 - Postmarketing Studies -- *2026 - Gabapentin as a Controlled Substance -- *2030 - Interstate Pharmacist Licensure -- *2037 - Support of the World Health Organization -- *2040 - Premarketing Comparative Clinical Studies -- *2043 - Drug Product Supply Chain Integrity -- 1904 - Notification of Drug Product Price Increases -- 1905 - Mitigating Drug Product Shortages -- 1906 - Emergency Supplies of Drug Products -- 1908 - 340B Drug Pricing Program Sustainability -- 1909 - Pharmacist Authority to Provide Medication-Assisted Treatment -- 1922 - Antimicrobial Use in Agriculture -- *1803 - Confidence in the U.S. Drug Approval and Regulatory Process -- 1815 - Impact of Drug Litigation Ads on Patient Care -- *1818 - Federal Quality Rating Program for Pharmaceutical Manufacturers -- 1819 - Intravenous Fluid Manufacturing Facilities as Critical Public Health Infrastructure -- 1713 - Partial Filling of Schedule II Prescriptions -- 1715 - Collaborative Practice -- 1716 - Greater "]
[{"$nulls":4},"Competition Among Generic and Biosimilar Manufacturers -- 1621 - Timely Board of Pharmacy Licensing."]
[{"$nulls":4},"1501 - Pharmacist Participation in Health Policy Development."]
[null,null,null,"Sommario/riassunto","More than half a century ago, ASHP developed its earliest proposed practice standard--the Proposed Minimum Standards for Pharmacies in Hospitals.    Today, ASHP continues to foster concrete improvements in pharmacy practice and in the therapeutic use of drugs with its annual compilation of ASHP guidance documents: ASHP Best Practices. These guidance documents have stimulated improvements in pharmacy practice and operations, influenced accreditation standards, laws, and regulations (both in the United States and in other countries), and contributed to an awareness among consumers and policymakers of the vital patient care role of pharmacists."]